<?xml version="1.0" ?>
<DOC>
   <DOCID>LA100594-0208</DOCID>
   <HEADLINE> BRIEFLY : HEALTH</HEADLINE>
   <TEXT> Carter-Wallace to Retrench : Faced with the collapse of profits from two of its key drugs , the New York-based company said it will slash its pharmaceutical research and sales staffs and curtail manufacturing . The use of the drugs -- Felbatol , an epilepsy medication suspected in 11 deaths , and Organidin , an asthma treatment pulled from the market in June -- was called into question by the Food and Drug Administration . Analysts said Carter-Wallace Inc. may eventually get_out of prescription_drugs altogether , leaving its future to consumer products .</TEXT>
</DOC>
